VolitionRx Limited (VNRX)
0.58
-0.01 (-1.36%)
At close: Feb 20, 2025, 3:59 PM
0.58
0.00%
After-hours: Feb 20, 2025, 04:10 PM EST
undefined% (undefined)
| Bid | 0.58 |
| Market Cap | 55.31M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -1.6 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.61 |
| Volume | 73,865 |
| Avg. Volume (20D) | 269,811 |
| Open | 0.58 |
| Previous Close | 0.59 |
| Day's Range | 0.58 - 0.61 |
| 52-Week Range | 0.43 - 1.10 |
| Beta | undefined |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company ope...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Mar 2, 2012
Employees 96
Stock Exchange AMEX
Ticker Symbol VNRX
Website https://www.volition.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VNRX stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 767.60% from the latest price.
Buy 50.00%
Hold 25.00%
Sell 0.00%
Next Earnings Release
VolitionRx Limited is scheduled to release its earnings on Mar 24, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
-7.19%
VolitionRx shares are trading lower after the comp...
Unlock content with
Pro Subscription
9 months ago
-14.53%
VolitionRx shares are trading lower after the company reported worse-than-expected Q1 sales results.
